📋 Tender Overview
Assessing The Role Of Intratumoral Microbiota In Therapy Responses Using Patient-Derived Tumor-On-Chip
"This Action Is Part Of The Cancer Mission Cluster Of Projects On Understanding (Tumour-Host Interactions)"".
Challenge: Primary Or Acquired Resistance To Therapies Is A Major Challenge In Oncology. Recent Research Suggests That Intratumoral Microbiota May Contribute To Anti-Cancer Drug Resistance, In Particular To Immunotherapies Such As Immune Checkpoint Inhibitors (Ici). However, Experimental Approaches To Address The Role Of Microbiota In Human Cancers Are Lacking.
Solution: Project Arturo Will Ethically Tackle This Problem By Using An Innovative State-Of-The-Art 3D Tumor-On-Chip (Toc) Model, As Part Of The Emerging Field Of Micro-Physiological Systems (Mps).
Plan: The Role Of Patient-Derived Bacteria, And Of Their Postbiotics And Released Extra-Cellular Vesicles, In Tumor Ecosystem Behaviors And Drug Responses, Will Be Deciphered By Integrating Clinical Data, Omics Analysis, And Novel Toc-Based Information (By Live Imaging And Single-Cell Transcriptomics). The Development Of Advanced Computational Methods To Extract Toc-Based Information Constitutes A Major Force And Innovation In The Field, With High Potential To Accelerate Future Applications Of Toc Technology In Clinics. The Focus Will Be On Two Frequent Poorly-Understood Cancer Subtypes: Non-Small Cell Lung Cancer (Nsclc) And Invasive Lobular Breast Cancer (Ilc). End-Users’ Perspectives Will Be Addressed Using A Co-Design Approach To Develop Ethically Sound And Evidence-Based Cancer-Related Innovation And Health Policies.
Impact: Arturo Results Are Expected To Lead To A Deep Understanding Of Processes Underpinning Tumor-Host Interactions, Helping To Conceive Novel Microbiota-Based Intervention Strategies, In Particular For Nsclc And Ilc Patients. Arturo Will Take Social, Ethnical, Cultural, And Gender Aspects Into Account, Facilitating The Translation Of Arturo~S Innovations To Clinical Practice And Co-Design Of Policies. Ultimately, The Arturo Impacts Will Be Far-Reaching, Contributing To Future Developments In Cancer Precision Medicine And Diagnostics And To The Eu Mission – Cancer."
Funded Under
Health
Total Cost
€ 5 248 985,00
Eu Contribution
€ 5 248 985,00
Coordinated By
Institut Curie
France
Start Date
1 July 2024
End Date
30 June 2028
Objective
"This action is part of the Cancer Mission cluster of projects on Understanding (tumour-host interactions)"".
Challenge: Primary or acquired resistance to therapies is a major challenge in oncology. Recent research suggests that intratumoral microbiota may contribute to anti-cancer drug resistance, in particular to immunotherapies such as immune checkpoint inhibitors (ICI). However, experimental approaches to address the role of microbiota in human cancers are lacking.
Solution: Project ARTURO will ethically tackle this problem by using an innovative state-of-the-art 3D tumor-on-chip (ToC) model, as part of the
